The study shows ECCT stands as a potential novel approach for treating breast cancer. This therapy employs low-intensity, intermediate-frequency electric fields and has exhibited promising outcomes in both laboratory experiments and trials conducted on mice. Research indicated that ECCT not only slowed the growth of cancer cells but also halted the growth of some cells entirely.
Key Findings
In Vitro Findings:
- Growth Inhibition: ECCT exposure significantly inhibited the proliferation of MCF-7 breast cancer cells by 28-39%, with the highest inhibition observed at 24 hours. This suggests that ECCT disrupts cellular processes critical for cancer cell survival and replication.
- Cellular Effects: Cells exposed to ECCT showed reduced proliferation rates and significant cell destruction during mitosis, indicating that ECCT interferes with the normal cell cycle, specifically during cytokinesis, leading to cancer cell death.
In Vivo Findings:
- Tumor Size Reduction: Mice injected with adenocarcinoma cells exhibited a significant tumor size reduction of over 67% following ECCT exposure. This substantial reduction demonstrates the efficacy of ECCT in shrinking tumors without the need for invasive procedures.
- Histopathology: No abnormal histopathological changes were observed in non-tumor tissues of ECCT-treated mice, highlighting the safety of ECCT. Tumor tissues showed extensive macrophage infiltration and the presence of apoptotic cells, suggesting an immune-mediated response to ECCT.
- Tumor Microenvironment: ECCT may alter TIF formation, affecting the tumor microenvironment. Changes in tumor texture suggest that ECCT disrupts the structural integrity of the tumor, potentially impairing cancer cell interactions and growth dynamics.
Safety and Efficacy:
- Histopathological Observations: The absence of damage in non-tumor tissues highlights the safety of ECCT. This is a crucial advantage over many conventional therapies that often harm healthy tissues.
- Selective Action on Tumor Cells: ECCT selectively targets cancer cells without affecting normal cells, minimizing adverse effects and maximizing therapeutic efficacy.
Cellular Proliferation and Apoptosis:
- Reduction in PCNA Expression: PCNA is a marker of cell proliferation. The significant reduction in PCNA expression in the IT group indicates that ECCT effectively inhibits the proliferative capacity of tumor cells, crucial for slowing tumor growth.
- Induction of Apoptosis: The increase in caspase-3 expression signifies enhanced apoptotic activity. ECCT promotes apoptosis, reducing the number of viable cancer cells and contributing to tumor shrinkage.
Inflammatory Cytokines:
- Down-Regulation of CCL2 and IL18: CCL2 and IL18 are involved in promoting inflammation and supporting tumor growth. Their down-regulation indicates a shift towards a less inflammatory and less supportive tumor microenvironment, less conducive to cancer progression.
